Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
News|Podcasts|June 27, 2025
Allen's Story: The Promising Potential of Intratumoral Immunotherapy
Advertisement
Allen Rappert, a St. Louis resident diagnosed with stage four squamous cell carcinoma, found hope through Dr. Jason Williams' intratumoral immunotherapy at the Williams Cancer Institute. Despite a grim prognosis, Allen's tumor was targeted directly, leading to his cancer-free status. Dr. Williams helped develop this treatment approach, which involves injecting immunotherapy drugs directly into tumors. Allen's case highlights the effectiveness of this method, which has a high success rate. Dr. Williams emphasizes the need for early treatment and shares his vision for future cancer care, advocating for immediate treatment at the time of biopsy.
Advertisement
Related to this article
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
ENDURANCE trial finds fixed 2-year lenalidomide maintenance matches continuous therapy for standard-risk multiple myeloma survival, guiding oncology pharmacists on MM regimen toxicity.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
FDA Grants Accelerated Approval to Ravulizumab for Proteinuria Reduction in IgA Nephropathy
4
Can AI Help Predict Drug Shortages?
5